

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



August 21, 2018

### Site of Care Drug Infusion/Injection Program

As stewards of healthcare expenditures for our subscribers, Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) is charged with ensuring the highest quality, evidence-based care for our members, while driving quality, safety, and affordability. In Provider Bulletin P27-18 posted on July 2, 2018, Blue Cross previously communicated that the Medical Policies listed below have a Site of Care requirement beginning September 3, 2018. This will apply to commercial subscribers requesting a new Prior Authorization (PA) or upon renewal of an existing PA. Please work with your infusion partners and/or Blue Cross Provider Services to ensure an appropriate in-network infusion setting is selected.

Please include the subscriber's identified Site of Care location in the PA form notes section within Availity. Unless subscribers meet the medical necessity criteria for hospital outpatient Site of Care below, the medication must be administered by an in-network provider at the following locations in order to receive coverage:

- In-Network clinic
- In-Network home health care
- In-Network infusion suite or center

### Not Applicable to Oncology Drugs

Site of Care does not apply to subscribers receiving treatment for Oncology. If a subscriber received notification that their drug is subject to the Site of Care Program AND they are currently utilizing the drug for oncology treatment, they will not be asked to move infusion/injection sites. No action is required, nor will they be stopped. Those subscribers can continue treatment as prescribed.

### Medical Policies Including Site of Care Requirements

- Abatacept, II-161
- Agalsidase Beta, II-26
- Alemtuzumab, II-184 (non-oncologic indications only)
- Alglucosidase Alfa, II-186
- Certolizumab Pegol, II-179
- Edaravone, II-178
- Golimumab (Simponi Aria), II-180
- Immunoglobulin Therapy, II-51
- Infliximab, II-97
- Natalizumab, II-49
- Ocrelizumab, II-185
- Rituximab, II-47 (non-oncologic indications only)
- Sebelipase Alfa, II-200
- Tocilizumab, II-181 (non-oncologic indications only)
- Ustekinumab, II-168
- Vedolizumab, II-182

QP68-18

Distribution: Available on providers.bluecrossmn.com. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Continued

## **Medical Necessity Criteria for Hospital Outpatient Site of Care**

At least ONE of the following criteria are met (documentation must be submitted):

- Age <18 years; or
- First dose OR <60 days from the first dose; or
- Reinitiating therapy after not being on therapy for  $\geq 6$  months; or
- Nearest non-hospital outpatient facility with infusion or injection capabilities is >30 miles from patient's home AND patient is not eligible for home infusion; or
- Changing IVIG or SCIG products; or
- Immunoglobulin A (IgA) deficiency with anti-IgA antibodies, for IVIG or SCIG; or
- History of a severe adverse event with prior infusion or injection therapy (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure); or
- History of adverse events with prior infusion or injection therapy (e.g., hypersensitivity or allergic reactions), which have not been successfully managed through standard premedication's or infusion rate adjustments; or
- Comorbidity or medical condition that increases the risk of an adverse event, including but not limited to the following:
  - o Cardiopulmonary conditions; or
  - o Inability to safely tolerate intravenous volume loads, including unstable renal function; or
  - o Difficult or unstable vascular access; or
- Physical or cognitive impairment such that infusion or injection in a non-hospital outpatient setting would present an unnecessary health risk; or
- Concurrent treatment with medications that require a higher level of monitoring (e.g., intravenous cytotoxic chemotherapy, blood products).

### **For more information, please visit:**

Procedures/Services/Drugs under the medical benefit:

- Go to: [providers.bluecrossmn.com](http://providers.bluecrossmn.com)
- Under Tools and Resources, select "Medical Policy" and acknowledge the Acceptance statement
- Select the "+" plus sign next to the Medical and Behavioral Health Policies
- Under the "Medical Policy Supporting Documents", Click on the Site of Care Program document link

### **Questions?**

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.